Evidence map›Paper›PMID 32451963›Full record

SynthesisAging clinical and experimental research2021

Verification of the predictive validity for mortality of the SARC-F questionnaire based on a meta-analysis.

Satoshi Ida, Ryutaro Kaneko, Kanako Imataka, Kaoru Okubo, Yoshitaka Shirakura, Kentaro Azuma, Ryoko Fujiwara, Hiroka Takahashi, Kazuya Murata

Abstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Aging clinical and experimental research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. SARC-F Predicts Mortality Risk of Older Adults during Hospitalization.The journal of nutrition, health & aging · 2021
    Article
  12. Screening Tools for Sarcopenia.In vivo (Athens, Greece)
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Satoshi IdaDepartment of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-21-chome, Ise-shi, FunaeMie, 516-8512, Japan. bboy98762006@yahoo.co.jp.
Ryutaro KanekoDepartment of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-21-chome, Ise-shi, FunaeMie, 516-8512, Japan.
Kanako ImatakaDepartment of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-21-chome, Ise-shi, FunaeMie, 516-8512, Japan.
Kaoru OkuboDepartment of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-21-chome, Ise-shi, FunaeMie, 516-8512, Japan.
Yoshitaka ShirakuraDepartment of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-21-chome, Ise-shi, FunaeMie, 516-8512, Japan.
Kentaro AzumaDepartment of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-21-chome, Ise-shi, FunaeMie, 516-8512, Japan.
Ryoko FujiwaraDepartment of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-21-chome, Ise-shi, FunaeMie, 516-8512, Japan.
Hiroka TakahashiDepartment of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-21-chome, Ise-shi, FunaeMie, 516-8512, Japan.
Kazuya MurataDepartment of Diabetes and Metabolism, Ise Red Cross Hospital, 1-471-21-chome, Ise-shi, FunaeMie, 516-8512, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAlthough the association between SARC-F questionnaire positivity and mortality has previously been studied, the results are inconsistent. Testing the predictive validity of the SARC-F questionnaire for clinically relevant outcomes of vital prognoses is important.

aimThe objective of this study was to test the predictive validity of SARC-F by conducting a meta-analysis on the association between SARC-F, a screening tool for sarcopenia, and mortality.

methodsThis meta-analysis used the MEDLINE, Cochrane Central Register of Controlled Trials, ClinicalTrials.gov, and Google Scholar databases for literature searches. Studies that examined the relationship between SARC-F questionnaire positivity and mortality and reported hazard ratios or odds ratios and 95% confidence intervals were included. A random-effects model was used for statistical analyses, and pooled hazard ratios, pooled odds ratios, and 95% confidence intervals were calculated.

resultsThrough the literature search, we found five studies (7501 individuals) that met the eligibility criteria for this study. The pooled hazard ratio for SARC-F questionnaire positivity and mortality was 1.87 (95% confidence interval 1.41-2.46; P < 0.001), indicating a significant association. The pooled odds ratio for SARC-F questionnaire positivity and mortality was 1.97 (95% confidence intervals 1.10-3.53; P = 0.02), showing a significant association.

conclusionsThere was a significant association between SARC-F positivity and future mortality, indicating the predictive validity of the SARC-F questionnaire.

trial registrationNot applicable.

Indexed as

SarcopeniaHumansMass ScreeningOdds RatioSurveys and QuestionnairesMeta-analysisMortalitySarcopeniaSkeletal muscle

Identifiers

PMID32451963

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.